The first step towards a compact and easy-to-use device is to determine a microfluidic solution that makes an analysis on a small sample of whole blood possible, that reduces the number of steps required and that makes to obtain the data feasible, reliable and economical. Viva In Vitro is already working on it hand in hand with some of the best European experts in microfluidic solutions for medical devices.
In addition, the Molecular Inflammation Group has the financial support of the Carlos III Health Institute in this regard. It is expected to have conclusive results in the first half of the year 2022.
This project observes the regulatory aspects and harmonized standards of application right from the beginning.
